Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Tracy Curley"'
Autor:
Wassim Abida, Daniel Vargas Pivato de Almeida, Erica Simone Dayan, Raymond E. Baser, Daniel C. Danila, Tracy Curley, Justine Anderson, Howard I. Scher, Gabrielle Arauz, Susan F. Slovin, Michael J. Morris, Karen A. Autio
Publikováno v:
Journal of Clinical Oncology. 38:e24174-e24174
e24174 Background: Incorporation of the PRO-CTCAE during chemotherapy is associated with fewer ER visits and improved survival. Limited data exist using this tool to capture irAE in immunotherapy trials. We collected select PRO-CTCAEs in a clinical t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3f139b9097c3abf7ab122d220766aeeb
https://doi.org/10.1200/jco.2020.38.15_suppl.e24174
https://doi.org/10.1200/jco.2020.38.15_suppl.e24174
Autor:
Yu Chen, Alba Torres, Kalyan Banda, Andrew C. Hsieh, Dana E. Rathkopf, Brett S. Carver, Tamara L. Lotan, Tracy Curley, Greg Shelkey, Howard I. Scher, Laura S Graham, Katie Pisano
BACKGROUND: MLN0128 is a first-in-class, dual mTOR inhibitor with potential to outperform standard rapalogs through inhibition of TORC1 and TORC2. This phase II study was designed to assess antitumor activity of MLN0128 in metastatic castration-resis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::292efdbefe396372502e97216e2ee947
https://europepmc.org/articles/PMC6050986/
https://europepmc.org/articles/PMC6050986/
Autor:
Lawrence H. Schwartz, Tracy Curley, Dana E. Rathkopf, Chaitanya R. Divgi, Xiaoyu Jia, Christina Hong, Neeta Pandit-Taskar, Anthony Delacruz, Joseph A. O'Donoghue, Steven M. Larson, David B. Solit, William Kevin Kelly, Gretchen Gignac, Ryan D. Stephenson, Howard I. Scher, Glenn Heller, Susan F. Slovin, Michael J. Morris, Jorge A. Carrasquillo
Publikováno v:
Journal of Clinical Oncology. 27:2436-2442
Purpose Early studies of patients with castration-resistant metastatic prostate cancer (CRMPC) suggest that chemotherapy administered with a dose of a bone-seeking radiopharmaceutical is superior to chemotherapy alone. To build on this strategy and f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ca42c35a1f464a8048161e96d101b8c
https://doi.org/10.1200/jco.2008.20.4164
https://doi.org/10.1200/jco.2008.20.4164
Autor:
Connie Collins, Glenn Heller, Michael A. Carducci, Samuel R. Denmeade, Martin Fleisher, Roberto Pili, Dana E. Rathkopf, Mario A. Eisenberger, Tracy Curley, Moshe A. Kelsen, Howard I. Scher, Susan F. Slovin, Michael J. Morris, Sharyn D. Baker, Melinda Halter
Publikováno v:
Journal of Clinical Oncology. 26:2959-2965
Purpose We evaluated rapid androgen cycling in combination with docetaxel for men with progressive noncastrate prostate cancers. Patients and Methods Noncastrate patients with ≤ 6 months of hormone therapy were eligible. Cohort 1 (62 patients) rece
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b398098c8b8956de5f283924f0a03b9c
https://doi.org/10.1200/jco.2007.15.1928
https://doi.org/10.1200/jco.2007.15.1928
Publikováno v:
Clinical journal of oncology nursing. 19(2)
Background Radium-223 dichloride, or radium-223, is a first-in-class alpha emitter that selectively targets bone metastases with high-energy, short-range alpha particles and is approved for the treatment of patients with castration-resistant prostate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c113d31dd404a9ffc7100792bd9c5a0a
https://pubmed.ncbi.nlm.nih.gov/25840395
https://pubmed.ncbi.nlm.nih.gov/25840395
Autor:
Lawrence H. Schwartz, Lee M. Krug, W. Kevin Kelly, Paul A. Marks, Judy H. Chiao, Stacie Richardson, Tracy Curley
Publikováno v:
Clinical Lung Cancer. 7:257-261
Background Histone deacetylase inhibitors are a novel class of therapeutic agents that inhibit deacetylate histones and other proteins involved in the regulation of gene expression and cell cycle progression. Phase I trials of intravenous and oral fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2047489c40a0df6aa3a43e5c74a0720
https://doi.org/10.3816/clc.2006.n.003
https://doi.org/10.3816/clc.2006.n.003
Autor:
Neeta Pandit-Taskar, Susan F. Slovin, Michael J. Morris, Joseph A. O'Donoghue, Jennifer Halpern, Tracy Curley, Peter Smith-Jones, Angelo Nacca, Anthony Delacruz, Ronald D. Finn, Lawrence H. Schwartz, Nyasha Warren, Steven M. Larson, W. Kevin Kelly, Maria Batraki, Chaitanya R. Divgi, Philip O. Livingston, Howard I. Scher, David B. Solit
Publikováno v:
Clinical Cancer Research. 11:7454-7461
Background: Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein primarily expressed on benign and malignant prostatic epithelial cells. J591 is an IgG1 monoclonal antibody that targets the external domain of the PSMA. The relati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8f3502626d86b61f19fc02ef1956bfe
https://doi.org/10.1158/1078-0432.ccr-05-0826
https://doi.org/10.1158/1078-0432.ccr-05-0826
Autor:
Lawrence H. Schwartz, Barbara MacGregore-Cortelli, Lee M. Krug, Howard I. Scher, Stacy Richardson, Mark L. Heaney, Semra Olgac, Tracy Curley, Elaina Chu, Victoria M. Richon, J. Paul Secrist, William P. Tong, Owen A. O'Connor, Judy H. Chiao, Paul A. Marks, William Kevin Kelly
Publikováno v:
Journal of Clinical Oncology. 23:3923-3931
Purpose To determine the safety, dosing schedules, pharmacokinetic profile, and biologic effect of orally administered histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in patients with advanced cancer. Patients and Methods Patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de575261fe083dad57ecfeee2edebb3b
https://doi.org/10.1200/jco.2005.14.167
https://doi.org/10.1200/jco.2005.14.167
Autor:
Tracy Curley, Louis Martone, W. Kevin Kelly, David Smith, Eric J. Small, Isan Chen, A. Dimitrios Colevas, Anthony Delacruz, William Oh, Matthew D. Galsky, Howard I. Scher
Publikováno v:
Journal of Clinical Oncology. 23:1439-1446
Purpose To evaluate the antitumor activity and safety of the epothilone B analog, ixabepilone, with or without estramustine phosphate (EMP), in chemotherapy-naive patients with progressive castrate metastatic prostate cancer. Patients and Methods Pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fec0e2458731d02104af58d46f4e5e94
https://doi.org/10.1200/jco.2005.09.042
https://doi.org/10.1200/jco.2005.09.042
Autor:
Tracy Curley, Howard I. Scher, Daniel C. Danila, Anuradha Gopalan, Erica Simone Dayan, James A. Eastham, Peter T. Scardino, Lawrence P. Bellomo, Phillip Wong, Vincent P. Laudone, Susan F. Slovin, Michael J. Morris, Wassim Abida, Karen A. Autio, Karim Touijer
Publikováno v:
Journal of Clinical Oncology. 35:203-203
203 Background: Androgen deprivation therapy (ADT) does not completely eliminate disease in mNCPC or BRPC. We explored a multimodality treatment (tx) approach combining ADT with ipilimumab (ipi) with the aim of achieving no evidence of disease or com
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fd42c758ab7c5e2ba6956c8310bbcf18
https://doi.org/10.1200/jco.2017.35.6_suppl.203
https://doi.org/10.1200/jco.2017.35.6_suppl.203